Sector: Health Care
Director information for ALDEYRA THERAPEUTICS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Ben R. Bronstein, M.D. | 76 | ["35 years in entrepreneurial and management roles in life science companies and venture capital firms","Interim Chief Medical Officer at Sentien Biotechnologies, Inc.","Executive Vice President, Clinical Development at Aclaris Therapeutics","Chief Medical Officer of Stealth BioTherapeutics, Inc.","Visiting Scholar at the Wyss Institute at Harvard Medical School","Founder or held senior management positions at several venture-backed life science companies"] | [] | 2026 | |
| Gary M. Phillips, M.D. | Director | 60 | ["Chief Business Officer of Anaveon AG","Chairman of the supervisory boards of Nanobiotix SA and BioConnection BV","President & CEO of OrphoMed, Inc.","Executive Vice President & Chief Strategy Officer at Mallinckrodt Pharmaceuticals plc","Head of global health at the World Economic Forum","President of Reckitt Benckiser Pharmaceuticals, Inc.","Executive roles at Merck KGaA, Novartis, and Wyeth","Healthcare strategy managing consultant at Towers Perrin","Medical officer with the United States Navy"] | [] | 2026 |
| Martin J. Joyce, M.B.A. | Director | 72 | ["Leadership roles in public and private medical device, biotechnology, and pharmaceutical companies from start-up stage to over $500 million in annual revenue","Experience in public company equity financing, business development, SEC reporting, strategic planning, mergers, acquisitions, investor relations, and biotechnology operations","Consultant to the life science industry since 2012","Chief Financial Officer at Lucid Inc. and BioSphere Medical","Managing Partner of Stratex Group LLC","Senior level positions at Serono Inc.","B.S. in finance from Northeastern University","M.B.A. from Suffolk University"] | [] | 2026 |
| Nancy B. Miller-Rich | Chief Executive | 67 | ["Founder of Miller-Rich Associates","Senior Vice-President at Merck Pharmaceuticals","P&L involvement in $38 billion pharmaceutical division","Closed approximately 300 deals producing $10 billion of value creation","Experience at Schering-Plough Corporation","Director of 4D Molecular Therapeutics, Inc.","Experience in commercial and marketing roles at Sandoz Pharmaceuticals and Sterling Drug, Inc.","B.S. in Business Administration, Marketing from Ithaca College"] | [] | 2026 |
| Neal S. Walker, D.O. | Director, Interim Chief Executive Officer | 57 | ["Chair of the board of directors at Aclaris Therapeutics, Inc.","Board-certified dermatologist","Serial entrepreneur with over 25 years of experience in the biopharmaceutical industry","Co-founder, President and CEO of Vicept Therapeutics, Inc.","Co-founder and led Octagon Research Solutions, Inc.","Chief Medical Officer at Trigenesis Therapeutics, Inc.","Led Cutix Inc."] | [] | 2026 |
| Richard H. Douglas, Ph.D. | Director | 73 | ["Senior Vice President, Corporate Development of Genzyme Corporation","Led Genzyme Corporation’s Corporate Development team from 1989 to 2011","Involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances","Served in science and corporate development capacities at Integrated Genetics","Currently on the board of directors of Novavax, Inc.","Chairs the Board of Directors of MaxCyte, Inc.","Member of the University of Michigan Innovation Partnerships National Advisory Board","Advisor to Red Sky Partners LLC"] | [] | 2026 |
| Todd C. Brady, M.D., Ph.D. | President and Chief Executive Officer | 54 | ["President and Chief Executive Officer since January 2012","served as Entrepreneur in Residence at Domain Associates, LLC","has served on the board of directors of biotechnology companies","holds a Ph.D. in pathology from Duke University","holds an M.D. from Duke University Medical School","holds an A.B. from Dartmouth College in Philosophy and Psychology"] | [] | 2026 |
| William D. Clark | Chief Executive Officer | 57 | ["more than three decades of leadership experience in the biopharmaceutical industry","Chief Executive Officer of Altido Therapeutics, Inc. since January 2026","Co-founder and Chief Executive Officer of Vibrant Biomedicines, Inc.","President and Chief Executive Officer of Genocea Biosciences, Inc. from 2011 until 2022","Chief Business Officer at Vanda Pharmaceuticals Inc.","Principal at Care Capital, LLC","10 years at SmithKline Beecham Corporation","MBA from The Wharton School at the University of Pennsylvania","BA from Harvard University","experience as a founder and executive officer of healthcare companies","substantial knowledge of the pharmaceutical industry"] | [] | 2026 |
